CSI Market
Sign In | Register

Neuropathix (TYGS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TYGS quarterly Cash Flow →
From Neuropathix through Dec 31 2017, changes in Dec 31 2021's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2021)
12 Months 		(Dec 31 2020) (Dec 31 2019) (Dec 31 2018) (Dec 31 2017)
Operating Activities
Income-3.56
Depreciation & amortization0.02
Amortization of Other Assets0.28
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation1.35
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Equity Securities Fv Ni Gain Loss-
Loss On Issuance Of Stock For Conversion Of Notes Payable And Accrued Salaries-
Stock Issued During Period Value Other-
Noninterest Expense-
Derivative Loss On Derivative-
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.00
Accounts Payable-0.01
Increase (Decrease) in Accrued Salaries0.33
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense0.04
Other Working Capital0.11
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.54
Discontinued operations0.00
Net Cash flow from Operating Activities-0.89
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Other Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments for (Proceeds from) Loans Receivable, Total0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.13
Long-term debt - repayments-0.07
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.83
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Series B Preferred Stock-
Proceeds From Convertible Notes Payable-
Proceeds From Convertible Notes Payable Net Of Oid-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.89
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.90
Total Cash Flow-0.01
4 historic quarters locked

Sign in to unlock the full Neuropathix cash flow history.

Sign In Create Free Account

About Neuropathix Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001607062-22-000388

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document